Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Ligand Pharmaceuticals (LGND) Total Debt (2016 - 2025)

Ligand Pharmaceuticals' Total Debt history spans 12 years, with the latest figure at $446.2 million for Q4 2025.

For Q4 2025, Total Debt changed N/A year-over-year to $446.2 million; the TTM value through Dec 2025 reached $446.2 million, changed N/A, while the annual FY2025 figure was $446.2 million, N/A changed from the prior year.
Total Debt for Q4 2025 was $446.2 million at Ligand Pharmaceuticals, roughly flat from $445.5 million in the prior quarter.
Across five years, Total Debt topped out at $446.2 million in Q4 2025 and bottomed at $76.6 million in Q3 2022.
The 3-year median for Total Debt is $95.9 million (2022), against an average of $206.1 million.